IP Verse

Dosage Forms For Tyk2 Inhibitors

Patent No. EP4031110 (titled "Dosage Forms For Tyk2 Inhibitors") was filed by Bristol Myers Squibb on Sep 18, 2020. The application was issued on Dec 24, 2025.

Patent Summary

Patent Family

Patent family tree
Statuses, jurisdictions and citation links are shared on request.

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
KERNEBECK PATENTANWALTSSep 24, 2026KERNEBECK
SCORPIOSep 24, 2026SAGITTARIUS
SANDOZSep 23, 2026TER MEER UND PARTNER

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

EP4031110

BRISTOL MYERS SQUIBB
Application Number
EP20781719A
Filing Date
Sep 18, 2020
Status
Granted And Under Opposition
Nov 21, 2025
Publication Date
Dec 24, 2025
External Links
Slate, Register , Google Patents